AKEBIA THERAPEUTICS INC (AKBA)
US00972D1054 - Common Stock
Taking everything into account, AKBA scores 2 out of 10 in our fundamental rating. AKBA was compared to 588 industry peers in the Biotechnology industry. AKBA may be in some trouble as it scores bad on both profitability and health. AKBA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AKBA has reported negative net income.
In the past year AKBA has reported a negative cash flow from operations.
In the past 5 years AKBA always reported negative net income.
AKBA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
AKBA's Return On Assets of -21.51% is amongst the best of the industry. AKBA outperforms 80.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.51% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-33.74%
ROA(5y)-39.44%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AKBA has a better Gross Margin (78.82%) than 87.20% of its industry peers.
In the last couple of years the Gross Margin of AKBA has declined.
The Profit Margin and Operating Margin are not available for AKBA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.02%
GM growth 5Y-3.88%
2. Health
2.1 Basic Checks
AKBA does not have a ROIC to compare to the WACC, probably because it is not profitable.
AKBA has more shares outstanding than it did 1 year ago.
AKBA has more shares outstanding than it did 5 years ago.
AKBA has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -8.48, we must say that AKBA is in the distress zone and has some risk of bankruptcy.
AKBA has a worse Altman-Z score (-8.48) than 74.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.48 |
ROIC/WACCN/A
WACC9.31%
2.3 Liquidity
AKBA has a Current Ratio of 1.18. This is a normal value and indicates that AKBA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.18, AKBA is doing worse than 86.52% of the companies in the same industry.
A Quick Ratio of 1.03 indicates that AKBA should not have too much problems paying its short term obligations.
The Quick ratio of AKBA (1.03) is worse than 87.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 1.03 |
3. Growth
3.1 Past
AKBA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.36%, which is quite impressive.
The Revenue for AKBA has decreased by -33.31% in the past year. This is quite bad
The Revenue has been decreasing by -1.29% on average over the past years.
EPS 1Y (TTM)36.36%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q100%
Revenue 1Y (TTM)-33.31%
Revenue growth 3Y-12.91%
Revenue growth 5Y-1.29%
Revenue growth Q2Q1.99%
3.2 Future
The Earnings Per Share is expected to grow by 43.82% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 17.44% on average over the next years. This is quite good.
EPS Next Y-5.64%
EPS Next 2Y-2.19%
EPS Next 3Y36.23%
EPS Next 5Y43.82%
Revenue Next Year-2.47%
Revenue Next 2Y-5.95%
Revenue Next 3Y6.98%
Revenue Next 5Y17.44%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AKBA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKBA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AKBA's earnings are expected to grow with 36.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.19%
EPS Next 3Y36.23%
5. Dividend
5.1 Amount
No dividends for AKBA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AKEBIA THERAPEUTICS INC
NASDAQ:AKBA (5/1/2024, 7:00:00 PM)
Premarket: 1.27 +0.03 (+2.42%)1.24
-0.02 (-1.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap259.62M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.51% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.82% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.18 | ||
| Quick Ratio | 1.03 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)36.36%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-5.64%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-33.31%
Revenue growth 3Y-12.91%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y